Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Cell Type-Specific Laser Capture Microdissection for Gene Expression Profiling in the Human Brain.

Mauney SA, Woo TW, Sonntag KC.

Methods Mol Biol. 2018;1723:203-221. doi: 10.1007/978-1-4939-7558-7_11.

PMID:
29344862
2.

Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response.

Graham HT, Rotroff DM, Marvel SW, Buse JB, Havener TM, Wilson AG, Wagner MJ, Motsinger-Reif AA; ACCORD/ACCORDion Investigators.

Front Genet. 2016 Aug 17;7:138. eCollection 2016.

3.

Weaving a Net of Neurobiological Mechanisms in Schizophrenia and Unraveling the Underlying Pathophysiology.

Bitanihirwe BK, Mauney SA, Woo TU.

Biol Psychiatry. 2016 Oct 15;80(8):589-98. doi: 10.1016/j.biopsych.2016.03.1047. Epub 2016 Mar 9. Review.

4.

Differentiation of oligodendrocyte precursors is impaired in the prefrontal cortex in schizophrenia.

Mauney SA, Pietersen CY, Sonntag KC, Woo TW.

Schizophr Res. 2015 Dec;169(1-3):374-380. doi: 10.1016/j.schres.2015.10.042. Epub 2015 Nov 14.

5.

Increased extracellular clusterin in the prefrontal cortex in schizophrenia.

Athanas KM, Mauney SL, Woo TW.

Schizophr Res. 2015 Dec;169(1-3):381-385. doi: 10.1016/j.schres.2015.10.002. Epub 2015 Oct 21.

6.

Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions.

Espeland MA, Probstfield J, Hire D, Redmon JB, Evans GW, Coday M, Lewis CE, Johnson KC, Wilmoth S, Bahnson J, Dulin MF, Green JB, Knowler WC, Kitabchi A, Murillo AL, Osei K, Rehman SU, Cushman WC; Look AHEAD Research Group; ACCORD Study Group.

Am J Hypertens. 2015 Aug;28(8):995-1009. doi: 10.1093/ajh/hpu292. Epub 2015 Feb 9.

7.

Molecular profiles of pyramidal neurons in the superior temporal cortex in schizophrenia.

Pietersen CY, Mauney SA, Kim SS, Lim MP, Rooney RJ, Goldstein JM, Petryshen TL, Seidman LJ, Shenton ME, McCarley RW, Sonntag KC, Woo TU.

J Neurogenet. 2014 Mar-Jun;28(1-2):53-69. doi: 10.3109/01677063.2014.882918. Epub 2014 Apr 10.

8.

Molecular profiles of parvalbumin-immunoreactive neurons in the superior temporal cortex in schizophrenia.

Pietersen CY, Mauney SA, Kim SS, Passeri E, Lim MP, Rooney RJ, Goldstein JM, Petreyshen TL, Seidman LJ, Shenton ME, Mccarley RW, Sonntag KC, Woo TU.

J Neurogenet. 2014 Mar-Jun;28(1-2):70-85. doi: 10.3109/01677063.2013.878339. Epub 2014 Mar 17.

9.

Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial.

Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC, Murray AM, Sullivan MD, Horowitz KR, Ding J, Marcovina S, Lovato L, Lovato J, Margolis KL, Davatzikos C, Barzilay J, Ginsberg HN, Linz PE, Miller ME; Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators.

JAMA Intern Med. 2014 Mar;174(3):324-33. doi: 10.1001/jamainternmed.2013.13656.

10.

Developmental pattern of perineuronal nets in the human prefrontal cortex and their deficit in schizophrenia.

Mauney SA, Athanas KM, Pantazopoulos H, Shaskan N, Passeri E, Berretta S, Woo TU.

Biol Psychiatry. 2013 Sep 15;74(6):427-35. doi: 10.1016/j.biopsych.2013.05.007. Epub 2013 Jun 19.

11.

Determinants of weight gain in the action to control cardiovascular risk in diabetes trial.

Fonseca V, McDuffie R, Calles J, Cohen RM, Feeney P, Feinglos M, Gerstein HC, Ismail-Beigi F, Morgan TM, Pop-Busui R, Riddle MC; ACCORD Study Group.

Diabetes Care. 2013 Aug;36(8):2162-8. doi: 10.2337/dc12-1391. Epub 2013 Feb 14.

12.

Crystal structure of the catalytic domain of UCHL5, a proteasome-associated human deubiquitinating enzyme, reveals an unproductive form of the enzyme.

Maiti TK, Permaul M, Boudreaux DA, Mahanic C, Mauney S, Das C.

FEBS J. 2011 Dec;278(24):4917-26. doi: 10.1111/j.1742-4658.2011.08393.x. Epub 2011 Nov 11.

13.

Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.

Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, Sullivan M, Horowitz KR, Ding J, Marcovina S, Lovato LC, Lovato J, Margolis KL, O'Connor P, Lipkin EW, Hirsch J, Coker L, Maldjian J, Sunshine JL, Truwit C, Davatzikos C, Bryan RN; ACCORD MIND investigators.

Lancet Neurol. 2011 Nov;10(11):969-77. doi: 10.1016/S1474-4422(11)70188-0. Epub 2011 Sep 28.

14.

Long-term effects of intensive glucose lowering on cardiovascular outcomes.

ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT.

N Engl J Med. 2011 Mar 3;364(9):818-28. doi: 10.1056/NEJMoa1006524.

15.

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I; ACCORD trial group.

Lancet. 2010 Aug 7;376(9739):419-30. doi: 10.1016/S0140-6736(10)60576-4. Epub 2010 Jun 30. Erratum in: Lancet. 2010 Oct 30;376(9751):1466.

16.

Effects of medical therapies on retinopathy progression in type 2 diabetes.

ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ.

N Engl J Med. 2010 Jul 15;363(3):233-44. doi: 10.1056/NEJMoa1001288. Epub 2010 Jun 29. Erratum in: N Engl J Med. 2011 Jan 13;364(2):190. N Engl J Med. 2012 Dec 20;367(25):2458.

17.

Effects of combination lipid therapy in type 2 diabetes mellitus.

ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP.

N Engl J Med. 2010 Apr 29;362(17):1563-74. doi: 10.1056/NEJMoa1001282. Epub 2010 Mar 14. Erratum in: N Engl J Med. 2010 May 6;362(18):1748.

18.

Effects of intensive blood-pressure control in type 2 diabetes mellitus.

ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F.

N Engl J Med. 2010 Apr 29;362(17):1575-85. doi: 10.1056/NEJMoa1001286. Epub 2010 Mar 14.

19.

Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials.

Mount DL, Feeney P, Fabricatore AN, Coday M, Bahnson J, Byington R, Phelan S, Wilmoth S, Knowler WC, Hramiak I, Osei K, Sweeney ME, Espeland MA; Look AHEAD and ACCORD Research Groups.

Clin Trials. 2009 Oct;6(5):416-29. doi: 10.1177/1740774509344440. Epub 2009 Sep 8.

20.

Effects of intensive glucose lowering in type 2 diabetes.

Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT.

N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.

Supplemental Content

Loading ...
Support Center